Wrapmanager Inc. Sells 3,996 Shares of Gilead Sciences, Inc. $GILD

Wrapmanager Inc. trimmed its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 43.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,304 shares of the biopharmaceutical company’s stock after selling 3,996 shares during the quarter. Wrapmanager Inc.’s holdings in Gilead Sciences were worth $589,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of the business. GoalVest Advisory LLC raised its position in Gilead Sciences by 7,566.7% during the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 227 shares during the last quarter. Corundum Trust Company INC acquired a new stake in shares of Gilead Sciences in the third quarter valued at about $26,000. Putney Financial Group LLC increased its stake in shares of Gilead Sciences by 53.4% in the second quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 94 shares during the period. Howard Hughes Medical Institute bought a new position in shares of Gilead Sciences during the second quarter worth about $30,000. Finally, MTM Investment Management LLC lifted its stake in shares of Gilead Sciences by 176.0% in the third quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 176 shares during the period. Institutional investors own 83.67% of the company’s stock.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 115,640 shares of the business’s stock in a transaction on Friday, January 23rd. The shares were sold at an average price of $135.00, for a total transaction of $15,611,400.00. Following the completion of the sale, the chief executive officer owned 566,698 shares in the company, valued at approximately $76,504,230. The trade was a 16.95% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Jeffrey Bluestone sold 5,000 shares of the firm’s stock in a transaction on Friday, November 28th. The shares were sold at an average price of $125.08, for a total transaction of $625,400.00. Following the completion of the transaction, the director directly owned 8,920 shares in the company, valued at $1,115,713.60. This trade represents a 35.92% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 319,891 shares of company stock valued at $45,091,556 in the last 90 days. 0.27% of the stock is currently owned by company insiders.

Gilead Sciences Price Performance

GILD stock opened at $149.83 on Tuesday. The stock has a market capitalization of $185.89 billion, a PE ratio of 22.13, a price-to-earnings-growth ratio of 2.01 and a beta of 0.36. The company’s 50-day moving average is $134.07 and its 200-day moving average is $124.08. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.68 and a quick ratio of 1.31. Gilead Sciences, Inc. has a 1 year low of $93.37 and a 1 year high of $157.29.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, beating analysts’ consensus estimates of $1.83 by $0.03. The business had revenue of $7.93 billion during the quarter, compared to analyst estimates of $7.68 billion. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The firm’s revenue was up 4.7% compared to the same quarter last year. During the same period in the previous year, the company posted $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Equities research analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, March 30th. Stockholders of record on Friday, March 13th will be given a dividend of $0.82 per share. The ex-dividend date of this dividend is Friday, March 13th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.79. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.2%. Gilead Sciences’s payout ratio is currently 48.45%.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead agreed to acquire Arcellx for an implied equity value of about $7.8 billion to gain full control of the Anito‑cel CAR‑T program — accelerates Gilead’s oncology pipeline and could deliver a near‑term product if regulatory timelines hold. Gilead Sciences to Acquire Arcellx — BusinessWire
• Positive Sentiment: Analysts reaffirming coverage and bullish price targets support the stock’s fundamental story — Needham reiterated a Buy with a $170 target, signaling continued institutional support. Needham reaffirmed buy on GILD — Benzinga
• Neutral Sentiment: Gilead announced management will present at multiple investor conferences in early March, providing more opportunities to detail the Arcellx rationale and upcoming catalysts. Gilead to present at investor conferences — BusinessWire
• Neutral Sentiment: Arcellx’s program has regulatory momentum (BLA acceptance reports), which underpins the strategic rationale but leaves remaining execution and integration risk for Gilead. Arcellx BLA accepted — TipRanks
• Negative Sentiment: A plaintiff‑side law firm has opened an investigation into the adequacy of the Arcellx sale process and price, introducing potential legal/transactional risk and distraction. KSF investigating Arcellx sale — BusinessWire
• Negative Sentiment: The deal price implies a ~68–80% premium to recent Arcellx levels, raising concerns about Gilead overpaying and the impact on capital allocation/valuation. Market participants are weighing strategic upside vs near‑term EPS/valuation dilution. Gilead to acquire Arcellx for up to $7.8B — Reuters
• Negative Sentiment: Broader market weakness in the session (Dow/tech softness) likely pressured Gilead alongside stock‑specific headwinds. Dow posts one‑day drop — Yahoo Finance

Analysts Set New Price Targets

GILD has been the subject of several analyst reports. TD Cowen raised their price target on shares of Gilead Sciences from $145.00 to $160.00 and gave the stock a “buy” rating in a report on Wednesday, February 11th. Deutsche Bank Aktiengesellschaft lifted their target price on shares of Gilead Sciences from $135.00 to $155.00 and gave the stock a “buy” rating in a research note on Wednesday, February 11th. Leerink Partners upped their price target on shares of Gilead Sciences from $146.00 to $148.00 and gave the company an “outperform” rating in a research report on Wednesday, February 11th. JPMorgan Chase & Co. increased their price target on Gilead Sciences from $150.00 to $160.00 and gave the stock an “overweight” rating in a report on Wednesday, February 11th. Finally, Argus boosted their price objective on Gilead Sciences from $135.00 to $165.00 and gave the company a “buy” rating in a research note on Thursday, February 19th. Twenty-three investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Gilead Sciences has an average rating of “Moderate Buy” and an average target price of $155.44.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.